Latest Listings And Ipos News

Tungsten Mining has secured $53 million to push its Mt Mulgine Project through critical feasibility stages while engaging international partners for processing and offtake. The company is positioning itself as a key player in the global tungsten market with strategic moves in the US and Europe.

BPH Global is nearing completion of its novel seaweed-based men’s health supplement, Project Popeye, as it moves toward TGA listing and scientific validation.

Zip Co has delivered a standout half-year performance with record cash earnings and upgraded FY26 guidance, driven by strong US market momentum and innovative product launches.

InvestSMART Group Ltd reports a solid half-year performance with funds under management reaching $750 million and a growing subscriber base, while outlining plans to enhance its digital wealth platform with AI and new services.

Global X Management (AUS) Limited has announced estimated distributions for three ETFs listed on the ASX AQUA Market for the period ending 28 February 2026, providing key dates and dividend reinvestment plan eligibility.

AuMEGA Metals has successfully upsized its institutional financing to C$30.1 million, anchored by Condire Investors who will hold nearly 20% of the company. The funds will accelerate exploration programs across its Newfoundland gold projects.

Bell Financial Group delivered a robust 17.1% rise in net profit after tax to $36 million for 2025, driven by strong growth in its Platforms division and a rebound in market activity. The company declared a fully franked final dividend of 6.5 cents per share, signalling confidence as it prepares to launch a new wealth management platform in 2026.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

PathKey.AI Ltd has responded to ASX inquiries about a recent spike in its share price and trading volume, confirming no undisclosed information is driving the market activity. The company points to its recent strategic update and funding completion as context for investor interest.

Cyclopharm has achieved a key milestone with Technegas approved for clinical use at the US National Institutes of Health, marking a strategic advance in its American expansion. Installation is imminent, leveraging a federal procurement framework that could broaden Technegas applications beyond pulmonary embolism.

Caterpillar has finalized its acquisition of RPMGlobal, paying shareholders A$5.00 per share and prompting RPMGlobal’s removal from the ASX. This marks a significant shift in the mining software landscape.